Development of diagnostic device to differentiate between bipolar and unipolar depression

开发区分双相和单相抑郁症的诊断设备

• 批准号: 103949
• 金额: $ 23.41万
• 依托单位: PSYOMICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103949
• 关键词: Development; diagnostic; device; differentiate; between

Bipolar disorder affects 2.4m people in the UK alone and has an estimated prevalence of around 2% globally, yet 40% of patients with bipolar disorder are misdiagnosed with depression and it takes an average of 7.5 years for the correct diagnosis to be reached. This leads to ineffective treatments, increased suicide risk, antidepressant-induced mania and higher healthcare costs, as well decreased quality of life for patients and their families. The long-term mission for Psyomics is improved prevention, diagnosis and treatment of mental health conditions. Our initial focus is on improved diagnosis of bipolar disorder and depression in primary care Recent research conducted by Psyomics and the Cambridge Centre for Neuropsychiatric Research has identified key biomarkers, assessed in dried blood spots and via a digital-screening approach that can differentiate these conditions with a strong predictive performance. This project will enable Psyomics to build on these results with the aim of launching a digital-only tool to support stratification in 2019 and a two-stage digital and biological diagnostic device to improve diagnosis and clinical outcomes for patients and their families in 2020.

双相情感障碍仅在英国就影响了240万人，估计全球患病率约为2%，但40%的双相情感障碍患者被误诊为抑郁症，平均需要7.5年才能得到正确的诊断。这导致无效的治疗，增加自杀风险，抗抑郁药诱导的躁狂症和更高的医疗费用，以及降低患者及其家人的生活质量。心理组学的长期使命是改善对心理健康状况的预防、诊断和治疗。我们最初的重点是改善初级保健中双相情感障碍和抑郁症的诊断最近由Psyomics和剑桥神经精神研究中心进行的研究已经确定了关键的生物标志物，通过干血斑和数字筛选方法进行评估，可以区分这些条件，具有很强的预测性能。该项目将使Psyomics能够在这些结果的基础上再接再厉，目标是在2019年推出一种仅支持分层的数字工具，并在2020年推出一种两阶段数字和生物诊断设备，以改善患者及其家属的诊断和临床结果。